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The prognosis for colorectal cancer (CRC) is generally poor, and
although surgery is an effective treatment, 50% of patients either
have metastatic or inoperable disease at the initial diagnosis or else
develop metastases and/or local recurrent disease within several
months (Boring et al, 1992). Although 5-fluorouracil (5-FU) is a
moderately effective chemotherapeutic option, many patients
either do not respond or progress after a brief response, and there-
fore an effective second-line chemotherapy option is needed. 
Until 1990, the search for salvage therapies for CRC patients
failing 5-FU-based chemotherapy regimens focused on new 5-FU
administration modalities. Continuous infusion and high-dose
(HD) 5-FU were investigated, but showed no significant benefit in
terms of efficacy, and its modulation using folinic acid (FA),
although showing an improved response rate, showed no benefits
in terms of survival (Advanced Colorectal Cancer Meta-Analysis
Project, 1992). The combination of 5-FU with other cytotoxic
agents, such as cisplatin, or interferon was also explored, with no
improvement in efficacy, and increased toxicity and morbidity
(Whitehead et al, 1991; Behrens et al, 1989; LoRusso et al, 1989;
Petrelli et al, 1989; Iyer et al, 1988; Hill et al, 1995). Since 1990,
the introduction of several new classes of antineoplastic agents
active in CRC patients, including oxaliplatin and irinotecan, has
opened up new therapeutic possibilities. 
Oxaliplatin – trans-l-diaminocyclohexane (DACH) oxalatoplat-
inum (Eloxatin®, Sanofi-Synthelabo, France) – is a DACH plat-
inum derivative whose main mechanism of action is the formation
of DNA intrastrand adducts between two adjacent guanines
d(GpG) or adjacent guanine and adenine d(GpA) bases. 
In vitro and in vivo data have shown oxaliplatin to be active
against CRC cell lines and synergistic with 5-FU, even in 5-FU
resistant cell lines (Raymond et al, 1998a; Raymond et al, 1998b).
Like other DACH platinums, it has also been shown to be only
partially cross-resistant with cisplatin or carboplatin in various
preclinical studies. Oxaliplatin is the first platinum compound to
show activity as a single agent when used in the treatment of
advanced CRC patients (Lévi et al, 1993). In two phase II studies
involving patients with fluoropyrimidine-resistant advanced CRC,
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Summary A statistical analysis was performed on the patient data collected from two compassionate-use programmes using oxaliplatin
(Eloxatin®) + 5-fluorouracil (5-FU) ± folinic acid (FA), to identify predictive factors for oxaliplatin-based salvage treatment in patients with 
5-FU-resistant advanced colorectal cancer (ACRC). 481 5-FU-resistant ACRC patients, most with performance status ≤ 2, ≥ 3 involved sites,
and ≥ 2 prior lines of chemotherapy, received oxaliplatin + 5-FU ± FA. Prognostic factors associated with overall response rate (ORR), time to
progression (TTP) and overall survival (OS) were identified using univariate and multivariate logistic and/or Cox proportional hazards
analyses. The ORR was 16% (95% CI: 13–20), the median TTP was 4.2 months (95% CI: 3.4–4.6), and the median OS was 9.6 months (95%
CI: 8.6–10.6). The multivariate analysis indicated poor (≥ 2 WHO) performance status (PS), a large number of prior chemotherapy regimens
(≥ 3), a low baseline haemoglobin level (< 10 g/dl), and a triweekly (vs biweekly) treatment administration schedule as significantly associated
(P < 0.05) with a lower ORR. Sex (male), number of organs involved (≥ 3) and alkaline phosphatase (AP) level (≥ 2 × the upper limit of normal)
were associated (P < 0.05) with shorter TTP. Poor PS, a large number of organs involved, and elevated AP were independently and
significantly correlated with shorter OS. Our analysis identified a relationship between efficacy results of oxaliplatin + 5-FU ± FA treatment in
5-FU-resistant ACRC patients and baseline prognostic factors related to PS, extent of disease and number of prior regimens. © 2001 Cancer
Research Campaign http://www.bjcancer.com 
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http://www.bjcancer.comtreated with oxaliplatin given as a single agent at 130 mg/m2 over a
2-h infusion every 3 weeks, the objective response rates (ORR)
were both 10%, with 24% and 40% of patients exhibiting disease
stabilization, and median overall survival times (OS) of 8.3 and 10
months (Machover et al, 1996). In a phase II trial by Bécouarn et
al, involving untreated CRC patients, oxaliplatin used as a single
agent produced a 27% ORR (95% CI: 13.8–44.1%), with a median
response duration of 195 days (range 126–364+), median time to
progression (TTP) of 127 days (range 22–364+), and median OS
of 395 days (range: 28–573+) (Becouarn et al, 1998). 
Oxaliplatin has also been given to patients progressing on 5-FU-
based regimens in phase II trials. Its addition to 5-FU + FA treat-
ment has produced ORRs ranging from 11% to 58%, depending on
patient characteristics and treatment scheme, with a median
progression-free survival (PFS) ranging from 7 to 10 months, and
a median OS of 12 to 17 months (De Gramont et al, 1997; Gerard
et al, 1997; Meyer et al, 1997; Levi et al, 1992; Bertheault-
Cvitkovic et al, 1996; Garufi et al, 1995; André et al, 1999). 
In a randomized phase III trial reported by Giacchetti et al, 200
non-pretreated metastatic CRC patients were given a chronomodu-
lated 5-FU + FA regimen either with or without the addition of
oxaliplatin at 125 mg/m2 q 3 weeks. The ORR was 53% in the
oxaliplatin arm (95% CI: 42–63%), and 16% in the oxaliplatin-
free arm (95% CI: 9–24%; P < 0.001). The median PFS in the
oxaliplatin and control arms were 7.9 and 4.3 months, respectively,
and the OS was 17.6 and 19.4 months, respectively (Giacchetti et
al, 2000). In another phase III randomized study, reported by de
Gramont et al, involving 420 previously untreated metastatic CRC
patients, the ORR was found to be 51% in the oxaliplatin-
containing arm and 23% in the control arm, with the median PFS
being 8.7 months in the oxaliplatin arm and 6.1 months in the
other, and with an OS of 15.9 and 14.7 months respectively (De
Gramont et al, 2000). While a survival advantage in first-line
therapy has not yet been demonstrated for oxaliplatin, as is
contrariwise the case for irinotecan (Douillard et al, 2000; Saltz et
al, 2000), investigation of oxaliplatin-based combinations in
pretreated and untreated CRC patients continues, and the present
article reports the activity of oxaliplatin + 5-FU ± FA in 5-FU
resistant CRC patients treated in the realistic clinical practice
setting of compassionate-use programmes. 
The compassionate-use programmes which are the subject of
this article comprised two cohorts, totalling 696 patients whose
disease had progressed on prior 5-FU-based chemotherapy. The
first European-wide cohort of 206 patients received oxaliplatin
between January 1994 and June 1995. Oncologists who wanted to
administer oxaliplatin to specific patients under this programme
applied to the programme’s sponsor. The second cohort of 490
patients were treated with oxaliplatin in France under an
Autorisation Temporaire d’Utilisation (ATU) starting in
September 1995 and implemented during the French application
review period, and continuing until marketing approval for the new
drug was granted in France (April 1996). All requests were moni-
tored by the French Agence du médicament. The two patient
cohorts of 5-FU-resistant patients treated with oxaliplatin plus
5-FU ± FA, which had already been the subject of safety assess-
ments in pursuit of their primary regulatory objective, were
analysed as a single group in order to identify factors predicting
the efficacy of oxaliplatin when added to 5-FU ± FA in a real-life
prescription context, including patients with source-reviewed and
third-party-assessed evidence of clinical 5-FU resistance. Efficacy
has been analysed in terms of ORR, median TTP and OS. 
MATERIALS AND METHODS 
Compassionate-use programme participants 
A total of 696 advanced CRC patients were recruited in both
compassionate-use programmes. All the patients received oxali-
platin with 5-FU ± FA. The first patient cohort, consisting of 206
patients, was treated in 44 European centres. The second patient
cohort, consisting of 490 patients was treated in 148 French insti-
tutions. 
Diagnosis and main inclusion guidelines 
The main inclusion criterion for the ATU was histologically
proven advanced/metastatic CRC. Patients were also to have
objective, verifiable resistance to 5-FU ± FA (on-treatment
progression) or to have contraindications for treatment with 5-FU,
in which case they were given oxaliplatin as a single agent. There
were no restrictions on age, performance status, or the number of
prior chemotherapy regimens. 
Data collection and patient classification 
All cases in the present cohort were thoroughly reviewed on-site
by a team of medical oncologists and all data were source-verified. 
Table 1 summarizes the information requested for each patient
in order for the physician and sponsor to identify which patients
were to receive oxaliplatin. After source review, all case report
forms were independently verified for completeness and consis-
tency. For each patient, the team reviewed prior therapies,
evidence of resistance to prior 5-FU treatment, dose and schedule
of 5-FU ± FA before and during oxaliplatin treatment, as well as
tumour response to the oxaliplatin-based treatment. 
In addition, an external panel of radiologists verified available
imaging evidence of progression during prior 5-FU-based treat-
ment for all patients included in the present cohort. Furthermore,
they reviewed all the oxaliplatin-treated patients whose disease
was reported to be responding or who showed stabilisation (≥ 9
weeks or 3 planned cycles). 
Identification of 5-FU-resistance 
After verification of patients’ characteristics, disease history and
disease progression under prior 5-FU treatment, and after the
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Table 1 Information collected for each patient 
Patient identification 
Start date of oxaliplatin-based treatment 
Age/sex 
Performance status 
Primary tumour site (colon or rectum) 
Prior therapies, especially chemotherapy 
Number of prior chemotherapy regimens 
Dose/schedule details of prior 5-FU-based treatment 
Organs involved 
Proof of progression while on prior 5-FU-based treatment 
Dose/schedule of Oxaliplatin +5-FU ± FA treatment 
Safety of oxaliplatin treatment 
Overall response while on oxaliplatin treatment 
Progression, with proof, if applicable 
Survival status at last visit 
Cause of death, if applicable external panel review, an algorithm was applied, based on treat-
ment modality and clinical, radiological evidence of 5-FU-
resistance, to reliably identify patients with 5-FU-resistant disease
(Figure 1). As a result of this assessment, 481 5-FU-resistant
advanced CRC patients were identified. These patients are the
subject of the univariate and multivariate analyses presented in this
article. 
Classification of 5-FU-based chemotherapy regimens 
Administration and schedule modalities for 5-FU (and for FA
when used as a modulating agent) were systematically recorded
for every previous regimen. 5-FU was administered according to
the preference of the individual prescribers, and hence in a very
wide variety of doses and schedules, both as a single agent and in
combination with various other cytotoxic or modulating agents.
For the purposes of the present analysis, the administration of 5-
FU (with or without FA), was defined according to the schedules
encountered in the patient cohort, as follows: 
  Bolus/short infusion administration (≤ 4 h) ± FA: either daily
(2–5 consecutive days), repeated weekly or every 3–4 weeks. 
  High-dose-intensity intermittent infusional schedule: this
encompassed all intravenous infusions ≥ 8 h and ≤ 48 h, given
at weekly or biweekly intervals, usually involving high total
doses of 5-FU (≥ 1000 mg/m2), ± FA. They were subdivided
into: 8-h weekly infusion, 48-h biweekly infusion (± 5-FU
bolus), and 24-h infusion, given weekly. 
  Continuous infusion: Intravenous continuous infusion
(< 1 000 mg/m2), ± FA for at least 4 days. These comprised:
4/5 days every 2–3 weeks given at a flat rate of delivery,
4/5 days continuous chronomodulated delivery, given every
2–3 weeks, + FA, or protracted continuous infusion lasting for
more than 10 consecutive days ± FA. 
Oxaliplatin dosing 
Oxaliplatin was administered either biweekly at doses ranging
from 80 to 100 mg/m2/cycle, usually associated with high-dose
infusional intermittent schedules, or every 3–4 weeks at doses
ranging from 100 to 130 mg/m2/cycle, associated with a wide
variety of 5-FU schedules and administration modalities.
Prescribers chose the schedule of oxaliplatin, all with similar
planned dose intensities (33–42 mg/m2/week), that they consid-
ered best adapted to the associated 5-FU-based regimen. 
Efficacy criteria 
Tumour response was assessed in conformity with World Health
Organization (WHO) criteria (Miller et al, 1981). Nevertheless, as
this was an ATU in unselected, heavily pretreated patients, the
assessments of antitumoural efficacy were not implemented at
regular intervals as in a formal clinical trial. The responses were
therefore defined according to the following modified WHO
criteria (modifications in italics): 
  Complete Response (CR): complete regression of all evidence
of tumour, where possible assessed in two evaluations at least
1 month apart. 
  Partial Response (PR): a ≥ 50% decrease in the sum of the
products of the two longest perpendicular diameters of all
measurable lesions with no increase in size of tumour or
appearance of any new lesion. As long as patients showed no
clinical or biological signs of progression in the 8 weeks
following their determination of PR, they were maintained in
this category. 
  Stable Disease (SD): < 50% decrease of measurable disease
and ≤ 25% progression of measurable lesion, as well as no
clinical, biological or radiological evidence of any new 
lesion. 
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                     5-FU Resistant
·  Progression during 5-FU treatment
·  Treatment-free interval between 5-FU and
   progressive disease ≤  6 months
·  Proof of progression −  radiological, clinical
   biological or surgical
                    (481 patients)
Group 2
Oxaliplatin combined with 5-FU ±  FA without
third-party verification of 5-FU resistance.
                    (197 patients)
Extended Access Programmes
Previous 5-FU-based therapy (696 patients)
(Source reviewed)
Group 1
Oxaliplatin as single agent.
(18 patients)
Group 4
Prior 5-FU regimen unchanged
with addition of oxaliplatin
        (314 patients)
Group 3
Prior 5-FU regimen modified
with addition of oxaliplatin
        (167 patients)
Figure 1 Criteria used to identify patient resistance to 5-FU   Progressive Disease (PD): ≥ 25% increase in the sum of the
products of two diameters of one or more measurable lesions,
evidence of new lesions, death from disease progression within
8 weeks of introduction of oxaliplatin or lack of formal disease
evaluation after 3 cycles of treatment. 
SD is a clinically relevant category in this analysis, as most
patients treated under this compassionate-use programme exhib-
ited PD under their previous treatment regimen. SD represents
a positive change in disease status for such patients, who have a
similar median OS to those exhibiting PR (Graf et al, 1994). 
Time-related parameters were also calculated, with median TTP
and OS being defined as the time elapsed between the start of
oxaliplatin-based treatment and the date when evidence of tumour
progression (clinical and/or radiological) was first obtained and
the date of patient’s death, respectively. 
Methods for statistical analysis 
TTP and OS curves for the various groups were computed using
the Kaplan-Meier method. Both univariate and multivariate
analyses were used to assess potential prognostic factors. For
univariate analyses, dichotomous (objective responses) and
censored (TTP and OS) data were compared by means of
Pearson’s χ 2 test and the log-rank test, respectively. The variables
included in the univariate analysis were: sex, age (< 60 or ≥ 60
years), PS, primary tumour site (colon or rectum), number of
involved organs (1, 2, or ≥ 3), number of prior chemotherapy
regimens for CRC (1, 2, ≥ 3), haemoglobin level, (< 10 g/dl or
≥ 10 g/dl), serum alkaline phosphatase (AP) level (< 2 × ULN or
≥ 2 x ULN), oxaliplatin schedule (biweekly or triweekly), change
of 5-FU scheme (yes or no), type of 5-FU + oxaliplatin delivery,
(bolus, HD or continuous infusion), study treatment regimen
(oxaliplatin + 5-FU, or oxaliplatin + 5-FU + FA), and patient
cohort (European or French). For the multivariate analysis,
dichotomous and censored data were compared by means of a
multivariate logistic model (Cox, 1970) and a Cox proportional
hazards model (Cox, 1972), respectively. A forward stepwise
procedure was used, based on the Wald statistic. The significance
level used as a criterion for retaining variables from the univariate
analysis for inclusion in the multivariate analysis was P ≤ 0.10. 
RESULTS 
Cohort characteristics 
Out of the 696 patients recruited, 481 (69%) were considered, after
source-data review and third-party verification, as having 5-FU-
resistant advanced CRC; 111 in the initial European ATU cohort
and 370 in the second French ATU cohort. Out of the 481 patients
confirmed as 5-FU resistant, 443 (92%) of these judgements were
based on radiological evidence of progression. The overall group
was 60% male, and 56% were over 60 years old. Only 9 of the
patients (2%) had a PS > 2 and 53 (11%) had a PS = 2 (see Table 2
for details of the patients’ characteristics). 
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Table 2 Patient pretreatment characteristics 
Characteristic European cohort French cohort All patients 
n = 111 n = 370 n = 481 
Sex 
Men/Women 58 / 53 230 / 140 288 / 193 
Age 
< 60 / ≥ 60 years 53 / 58 159 / 211 212 / 269 
WHO PS 
0 / 1 / 2 / 3 / MD 46 / 46 / 14 / 5 / 0 144 / 168 / 39 / 4 / 15 190 / 214 / 53 / 9 / 15 
Primary tumour site 
Colon/rectum 69/42 259 / 111 328 / 153 
Initial Duke’s stage 
A / B / C / D / MD 2 / 11 / 26 / 70 / 2 3 / 48 / 118 / 193 / 8 5 / 59 / 144 / 263 / 10 
Number of metastatic sites 
1 / 2 / ≥ 3 / MD 48 / 31 / 32 / 0 188 / 127 / 51 / 4 236 / 158 / 83 / 4 
Organs involved 
Liver 93 292 385 
Lung 43 112 155 
Lymph nodes 31 51 82 
Peritoneum 14 56 70 
Other 14 24 38 
Number of prior CT lines 
1 / 2 / ≥ 3 59 / 26 / 26 123 / 132 / 115 182 / 158 / 141 
Patients receiving 1 prior CT line in adjuvant setting as only prior treatment 9 14 23 
Interval between diagnosis of recurrence and oxaliplatin treatment 
0–≤ 12 months 59 182 241 
>12–≤ 24 months 37 107 144 
>24 months 15 81 96 
Interval between last CT cycle and oxaliplatin treatment 
0–≤ 3 months 95 291 386 
> 3–≤ 6 months 14 67 81 
> 6 months 2 12 14 
MD, missing data; CT, chemotherapy. Out of the 471 patients for whom data concerning staging at
diagnosis was available, 64 (14%) initially presented with a
Duke’s stage of A or B, 144 (31%) with stage C, and 263 (56%)
with stage D. Apart from the 4 patients for whom data on metas-
tases were missing, 236 (49%) had only one metastatic site, 158
(33%) had two, and 83 (17%) had three or more. Involvement of
the liver predominated, being found in 385 patients (80%),
followed by the lung in 155 patients (32%), lymph nodes in 82
patients (17%) and the peritoneum in 70 patients (15%). 
There were 141 patients (29%) who had received 3 or more lines
of chemotherapy prior to treatment with oxaliplatin, 158 (33%)
who had received 2, and 182 patients (38%) who had received 1
prior chemotherapy regimen. Adjuvant chemotherapy was admin-
istered to 140 patients (29%). The time interval between the last
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Table 3 Univariate analysis of objective response rate (ORR), time to progression (TTP), and overall survival (OS) following the addition of oxaliplatin to a
5-FU ± FA regimen in 5-FU-resistant colorectal cancer patients 
Parameter Number of patients ORR TTP OS 
% P Median (mo) P Median (mo) P
All patients 481 16.4 4.2 9.6 
Cohort NS NS 
Europe (first) 111 22.5 0.048 4.1 9.6 
France (second) 370 14.6 4.3  9.7 
Sex NS NS 
Men 288 16.7 4.1 0.0305 9.5 
Women 193 16.1 4.8 9.9 
Age NS NS NS 
<60 212 16.0 4.3 10.2 
≥ 60 269 16.7 4.2 9.3 
Performance statusa
0 190 21.1 0.024 4.6 <0.0001 12.5 <0.0001 
1 214 13.6 4.3 9.3 
2 53 9.4 2.8 4.6 
3 9 0 0.8 1 
0–1 404 17.1 0.071 4.5 <0.0001 10.6 <0.0001 
2–3 62 8.1 1.9 3.6 
0 190 21.1 0.013 4.6 <0.0001 12.5 <0.0001 
1–2 267 12.7 4.0 8.6 
3 9 0 0.8 1.0 
Primary tumour site NS NS NS 
Colon 328 15.9 4.1 9.6 
Rectum 153 17.6 4.5 9.8 
Number of disease sitesa NS 
1 236 16.5 4.7 <0.0001 11.9 <0.0001 
2 158 15.8 4.2 9.6 
≥ 3 83 16.9 2.8 6.2 
1 236 16.5 NS 4.7 0.0001 11.9 0.0004 
≥ 2 241 16.2 3.8 8.2 
Number of prior CT lines NS 
1 182 23.6 <0.0001 4.6 0.0309 10.7 
2 158 16.5 4.6 9.1 
≥ 3 141 7.1 3.2 9.8 
Haemoglobin 
<10 g/dl 50 4.0 0.012 2.3 0.0584 6.7 0.0123 
≥ 10 g/dl 416 18.0 4.5 9.9 
Serum APa
<2 × ULN 308 19.5 0.006 4.5 0.0175 11.0 <0.0001 
≥ 2 × ULN 119 8.4 3.8 7.4 
Oxaliplatin schedule NS NS 
Biweekly 85 29.4 0.001 5.4 11.1 
Triweekly 370 14.6 4.1 9.9 
Change of 5-FU scheme NS NS  NS 
Yes 167 15.0 4.4 9.9 
No 314 17.2 4.1 9.6 
5-FU delivery + oxaliplatina NS NS NS 
Bolus 77 13.0 4.3 9.1 
High dose 273 15.8 3.9 9.3 
Continuous infusion 58 17.2 4.7 10.4 
Oxaliplatina NS NS 
+5-FU 374 14.7 0.070 4.2 9.9 
+5-FU +FA 104 22.1 4.1 9.5 
aMissing data. NS, not significant; CI, confidence interval; AP, alkaline phosphatase; CT, chemotherapy; mo, months; ULN, Upper Limit of Normal. regimen and the beginning of oxaliplatin treatment was less than
three months for 386 of the patients (80%), between 3 and 6
months for 81 (17%) and greater than 6 months for the remaining
14 patients (3%). 
Antitumour activity 
In the European cohort of 111 5-FU-resistant patients, an objective
response to oxaliplatin with 5-FU with or without FA was reported
in 25 patients, giving a 23% ORR (95% CI: 15–31%). For the
French cohort of 370 patients, an objective response to oxaliplatin-
based treatment was reported in 54 patients, resulting in a 15%
ORR. (95% CI:11–18%). The ORR reported for both groups
combined (481 patients) was 16% (95% CI:14–20%). Response
rates and time-related parameters according to various variables
analysed are presented in Table 3, and the results of the multi-
variate analysis are presented in Table 4. 
Disease stabilization (SD) was recorded in 185 patients of the
combined cohort of 481 (38%), of whom 161 (87%) had a TTP of
more than 16 weeks. The median duration of SD was 5.7 months
(range, 1.5–25.8). 
According to the univariate analysis, having a PS of 0 was found
to be positively correlated with ORR (P = 0.024), and according to
the multivariate analysis, having a PS of 0–1 was highly signifi-
cant (P = 5 × 10–4). The number of prior chemotherapy regimens
received was negatively correlated with ORR achieving high
significance in the univariate analysis
(P < 1 × 10–4). It is of note that an ORR of 23.6% was recorded in
patients having received one prior chemotherapy regimen, while
according to the multivariate analysis, receiving ≥ 3 prior
chemotherapy regimens was highly correlated with a lower likeli-
hood of response (ORR = 7% vs 24% for 1 regimen, P = 0.0054). 
Haemoglobin level < 10 g/dl at baseline showed a significant
negative correlation with ORR (4% vs 18% for ≥ 10 g/dl) in both
the univariate (P = 0.012) and multivariate (P = 0.0018) analyses.
Although a baseline serum AP level < 2 × the upper limit of
normal (ULN) was highly positively correlated with ORR (20% vs
8% for ≥ 2  ULN) according to the univariate analysis, it had no
independent significance in the multivariate analysis. 
Biweekly oxaliplatin + 5-FU ±FA schedules were found to be
positively correlated with ORR (29% vs 15% for the triweekly
schedules) and was identified as a highly significant factor for the
likelihood of objective response in both analyses. Oxaliplatin
administered with both 5-FU and FA, compared to oxaliplatin with
5-FU alone (mostly as a continuous infusion, either 4–5 days q 3
weeks or a protracted continuous IV) exhibited a trend towards
higher ORR (22% vs 15%, respectively), but this relation failed to
reach statistical significance. 
Time-related parameters 
Female sex was found to be positively and significantly correlated
with TTP (4.8 months vs 4.1 for male patients) in both the
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Table 4 Multivariate analysis of objective response rate (ORR), time to progression (TTP), and overall survival (OS) following the addition of oxaliplatin to a 
5-FU ± FA regimen in 5-FU-resistant colorectal cancer patients 
ORR (n = 393) TTP (n = 408) OS (n = 412) 
Parameter P Relative risk [95% CI] P Relative risk [95% CI] P Relative risk [95% CI] 
Cohort NS NA NA 
Europe (first) 
France (second) 
Sex NA 0.0022 0.71[0.58–0.89] NA 
Male 
Female 
PS 0.005 3.01 [1.62–5.60] 0.0002 1.75  [1.30–2.36] <0.0001 2.34 [1.68–3.24] 
0–1 
2–3 
Number of disease sites NA 0.0005 <0.0001 
1 –– –
2 0.0409 1.27 [1.01–1.60] 0.0909 1.27 [0.96–1.67] 
≥ 3 0.0001 1.75 [1.31–2.33] <0.0001 2.05 [1.50–2.80] 
Number of prior lines of chemotherapy 0.0134 NS NA 
1 – 
2 NS 
≥ 3 0.0054 0.39 [0.20–0.76] 
Haemoglobin 0.0018 0.37 [0.20–0.69] NS NS 
<10 g/dl 
≥ 10 g/dl 
Serum alkaline phosphatase NS 0.067 1.37 [1.09–1.72] <0.0001 1.88 [1.45–2.44] 
<2 × ULN 
≥ 2 × ULN 
Oxaliplatin NS NA NA 
+5-FU 
+5-FU + FA 
Rhythm <0.0001 0.18 [0.10–0.30] NA NA 
Biweekly 
Triweekly 
NS, not significant; NA, not analysed; CI, confidence interval; ULN, Upper Limit of Normal. univariate and the multivariate analysis. Having a PS of 0 was
positively correlated with both TTP and OS: in the univariate
analysis, PS = 0 was found to be a highly significant factor (P < 1
× 10–4) for both TTP (median 4.6 months) and OS (median 12.4
months), and the multivariate analysis confirmed its independent
prognostic value. The number of involved organs had significant
prognostic correlations, with single organ involvement being posi-
tively correlated with both median TTP and OS in the univariate
and multivariate analyses, when compared to patients with either 2
or ≥ 3 involved organs 
Although having received only one prior chemotherapy regimen
was positively correlated with median TTP (4.6 months), when
compared to patients receiving ≥ 2 regimens (3.2 months) by
univariate analysis (P = 0.031), this factor lost its significance in
the multivariate analysis. The number of prior chemotherapy regi-
mens failed to show statistical significance for OS in either
analysis. Baseline haemoglobin <10 g/dl was negatively correlated
with TTP (median 2.3 months vs 4.5 for ≥ 10 g/dl) and signifi-
cantly so for OS (median 6.7 months v 9.9 for ≥ 10 g/dl), but the
multivariate analysis did not show this factor to be significant.
Serum AP level < 2 × ULN was significantly positively correlated
with TTP (median 4.5 months vs 3.8 for ≥ 2 × ULN) and the corre-
lation was highly significant for OS (median 11.0 months vs 7.4
for ≥ 2 × ULN; P < 1 × 10–4). The multivariate analysis confirmed
its independent prognostic value. 
DISCUSSION 
The aim of the present statistical analysis was to identify factors
that will serve as prognostic indicators for oxaliplatin/5-FU
patients who have proven resistant to 5-FU. Once the first-line 5-
FU regimen had failed, the only alternatives with some evidence of
activity available at the time were modulations of the 5-FU
regimen through addition of FA or interferon, or the administration
of the 5-FU-containing treatment using different doses and/or
schedules (Streit et al, 1997; Izzo et al, 1994; Falcone et al, 1994;
Iyer et al, 1988). At the time of the first cohort’s treatment,
irinotecan had not yet been approved for this indication, and so the
therapeutic choices for CRC patients failing 5-FU-based treatment
were extremely limited. Thus, only 3 patients in the European
cohort (2.7%) had previously received irinotecan, while 67
patients (18.1%) of the subsequent French cohort had done so,
reflecting the timing of compassionate-use and commercial avail-
ability of irinotecan. 
We should stress that 62% of the patients had already received
two or more lines of chemotherapy for their advanced CRC prior
to the administration of the oxaliplatin-containing treatment.
Furthermore, the number of prior lines of chemotherapy was corre-
lated with another possibly relevant variable; the interval between
the diagnosis of metastatic disease and the introduction of the
oxaliplatin treatment. The univariate analysis revealed a significant
difference in ORR (P < 0.05) between the 2 cohorts (23% for the
European cohort, 15% for the French). This result is probably
associated with the difference in the median number of lines of
prior chemotherapy between the two groups (1 for the European
cohort, and 2 for the French). 
The irinotecan pretreated patients of the French cohort regis-
tered an ORR of only 6.0% versus 20.0% in irinotecan-naive
patients. However, the higher rate of exposure to irinotecan in the
second cohort would not appear to explain the difference for ORR
between the two cohorts, as irinotecan pretreatment was not found
to be an independent prognostic factor for ORR in a multivariate
analysis carried out on the French cohort (data not shown).
Nevertheless, irinotecan pretreatment was a predictor of shorter
TTP and OS in that cohort. Median TTP in irinotecan pretreated
and non-pretreated patients of the French cohort was 2.4 and 4.5
months, respectively, and median OS 6.6 and 9.0 months. Given
the arrival of irinotecan as a standard agent in first-line treatment
of metastatic CRC, with significant consequences for therapeutic
options in progressing patients, the optimization of sequential ther-
apeutic possibilities is a pressing need, and is the subject of an
ongoing phase III comparison of irinotecan + 5-FU/FA followed
by oxaliplatin + 5-FU/FA versus the inverse sequence (Tournigand
et al, 2001). 
When considering baseline patient and disease characteristics,
PS is clearly a major predictive factor for response, TTP and OS in
5-FU-resistant CRC patients. The number of prior chemotherapy
regimens is a key factor for likelihood of response, but is less
indicative of the duration of TTP and OS. Haemoglobin level at
baseline was significantly linked to response rate, although the
significance of this factor for TTP and OS elicited by the univariate
analysis was not confirmed by the multivariate assessment.
Similarly, although serum AP level proved to be a significant
factor for response rate according to the univariate analysis, this
was not confirmed by the multivariate analysis. Nevertheless, this
variable is independently correlated with both TTP and, more
importantly, OS and is thus clinically relevant. 
As far as administration regimens and schedules are concerned,
the multivariate analysis suggested that biweekly oxaliplatin + FU
± FA administration schedules were a highly significant positive
factor for obtaining a response. However, this factor was not
significant as far as TTP and OS were concerned. Since there were
no guidelines for the frequency of response assessments, and since
there is a tendency to higher frequency assessments in the centres
that enrol the greatest numbers of patients, the clinical relevance of
this statistical relationship remains moot. For example, the French
hospitals Saint Antoine and Paul Brousse, being the institutions
with the greatest experience with oxaliplatin + 5-FU ± FA, treated
a large number of patients in this compassionate-use programme
due to the absence of clinical trials at the time, or patient ineligi-
bility for available trials. These patients were nevertheless
managed in the same manner as those included in the formal clin-
ical trials. Likewise, the analysis revealed a tendency towards a
higher ORR in biweekly regimens, but there is no prospectively
controlled data available to confirm this result. Interestingly,
changing the 5-FU regimen when oxaliplatin was introduced into
the treatment had no bearing on ORR, TTP or OS, calling into
question the value of any specific strategy that might be pursued
when associating oxaliplatin with a prior 5-FU regimen. 
When the data from this study are compared with the efficacy
data obtained in formal phase II studies in 5-FU-pretreated CRC
patients, which necessarily enforce positive selection through
restrictive eligibility criteria, the time-related efficacy parameters
are similar, but the ORR is lower (16.4% vs 24–55%) (De Gramont
et al, 1997; Gerard et al, 1997; Meyer et al, 1997; Levi et al, 1992;
Bertheault-Cvitkovic et al, 1996; Garufi et al, 1995; André et al,
1999). This difference in ORR is very possibly due to both the lack
of eligibility criteria and the lack of enforced regular evaluations in
the compassionate-use programs, which contrast with the uniform
evaluation methodology required in clinical trials, and so influ-
ences the interpretation of results (Warr et al, 1984). Other factors
resulting in the different ORRs may well be the lack of restriction
Factors predicting oxaliplatin efficacy 515
British Journal of Cancer (2001) 85(4), 509–517 © 2001 Cancer Research Campaignon PS and the number of prior lines of chemotherapy for patients
included in the present analysis. Another consideration is the
importance of disease stabilization as a positive therapeutic
outcome in the treatment of 5-FU-resistant advanced CRC patients
(38.5% in this analysis) that is not considered in the determination
of the ORR. This could explain why the TTP and OS are very
close to those found in other studies, while the ORR is lower. The
key parameter, OS, falls well within other published data from
formal trials, and lends particular strength to the current analysis;
as a matter of fact, patients potentially eligible for Phase II second-
line CRC trials (good PS, ≤ 2 lines, good haemoglobin, etc.), show
time-related progression parameters strictly similar to those
reported in other studies (De Gramont et al, 1997; Gerard et al,
1998; André et al, 1999). 
The present analysis confirms the activity of the oxaliplatin/5-FU
± FA combination as an active treatment for progressive 5-FU-resis-
tant CRC patients. Although not strictly comparable, the results
obtained in this heterogeneous, non-restricted cohort of 5-FU-resis-
tant CRC patients, especially with respect to time-related parame-
ters, compare favourably to those published for single-agent
irinotecan following formal phase II–III trials including patients
with similar disease characteristics (Rougier et al., 1998). The
formal comparison between irinotecan and oxaliplatin/5-FU in 5-
FU-pretreated CRC patients is warranted, but may come to be of
secondary importance for therapeutic decision-making in the 5-FU
refractory context in light of several reports showing their combina-
tion to be feasible and active in this patient population (Wasserman
et al, 1999; Goldwasser et al, 2000; Bécouarn et al, 2001). 
The patient’s prognosis in such cases depends significantly on
several factors discussed in this paper. The interest of oxali-
platin/5-FU as a therapeutic option in 5-FU-resistant cancer
appears well supported by the results of the analysis of this ‘real-
life’ prescription context. Its value appears enhanced when
patients are treated earlier in their disease development and before
the general deterioration of the patient’s condition. 
To conclude, this experience confirms the preclinical and clin-
ical data reported in phase II–III studies concerning the synergy
and activity of oxaliplatin in combination with 5-FU ± FA in 5-
FU-resistant patients. Our analysis fails to show any strong rela-
tionship between 5-FU ± FA delivery modalities and time-related
parameters. Finally, the efficacy of oxaliplatin-based combination
treatment in this population is dependent on well-recognized
factors related to patients’ general status and pre-treatment history
as well as the extent of their disease. 
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